Vor Biopharma Inc.

NasdaqGS:VOR Stock Report

Market Cap: US$409.7m

Vor Biopharma Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Jean-Paul Kress

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownershipn/a
Management average tenureless than a year
Board average tenure3yrs

Recent management updates

Recent updates

Vor Biopharma: Initiating Hold Rating On Durable Telitacicept MG Study Data

Dec 18

Vor Biopharma Inc.'s (NASDAQ:VOR) Intrinsic Value Is Potentially 55% Above Its Share Price

Oct 11
Vor Biopharma Inc.'s (NASDAQ:VOR) Intrinsic Value Is Potentially 55% Above Its Share Price

We Think Vor Biopharma (NASDAQ:VOR) Needs To Drive Business Growth Carefully

Sep 11
We Think Vor Biopharma (NASDAQ:VOR) Needs To Drive Business Growth Carefully

Calculating The Intrinsic Value Of Vor Biopharma Inc. (NASDAQ:VOR)

Jun 25
Calculating The Intrinsic Value Of Vor Biopharma Inc. (NASDAQ:VOR)

We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

Apr 08
We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

Vor Biopharma: Short On Cash, Too Much Uncertainty For Now

Feb 24

We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

Dec 24
We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

Vor Biopharma (NASDAQ:VOR) Will Have To Spend Its Cash Wisely

Sep 10
Vor Biopharma (NASDAQ:VOR) Will Have To Spend Its Cash Wisely

We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

May 24
We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

Here's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn Situation

Dec 05
Here's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn Situation

Will Vor Biopharma (NASDAQ:VOR) Spend Its Cash Wisely?

Aug 18
Will Vor Biopharma (NASDAQ:VOR) Spend Its Cash Wisely?

Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

May 05
Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

Is Vor Biopharma Inc. (NASDAQ:VOR) Trading At A 49% Discount?

Mar 13
Is Vor Biopharma Inc. (NASDAQ:VOR) Trading At A 49% Discount?

We Think Vor Biopharma (NASDAQ:VOR) Needs To Drive Business Growth Carefully

Oct 19
We Think Vor Biopharma (NASDAQ:VOR) Needs To Drive Business Growth Carefully

Vor Bio appoints Eyal C. Attar as chief medical officer

Oct 12

Is Vor Biopharma (NASDAQ:VOR) In A Good Position To Invest In Growth?

Jun 18
Is Vor Biopharma (NASDAQ:VOR) In A Good Position To Invest In Growth?

Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

Mar 05
Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

Aug 30
Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

Vor Biopharma: Targeted Therapies For Transplants

Jun 30

We're Not Very Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

May 10
We're Not Very Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

CEO

Jean-Paul Kress (60 yo)

less than a year
Tenure

Dr. Jean-Paul Kress, M.D., is Chairman & Chief Executive Officer of Vor Biopharma Inc. from June 25, 2025. Dr. Kress is Independent Director of Sanofi from January 1, 2025. Dr. Kress had been the Chief Exe...

Leadership Team

NamePositionTenureCompensationOwnership
Robert Ang
Strategic Advisorless than a yearUS$2.22m0.017%
$ 67.7k
Jean-Paul Kress
Chairman & CEOless than a yearno datano data
Siddhartha Mukherjee
Scientific Founder & Chairman of Scientific Advisory Boardno datano datano data
Sandesh Mahatme
Chief Business Officer & CFOless than a yearno datano data
Adi Osovsky
General Counselless than a yearno datano data
Carol Lincoln
Head of Human Resourcesno datano datano data
Qing Zuraw
Executive Officerless than a yearno datano data
Dallan Murray
Chief Commercial Officerless than a yearno datano data
Navid Khan
Chief Medical Affairs Officerless than a yearno datano data
Jeremy Sokolove
Chief Medical Officerless than a yearno datano data
0.5yrs
Average Tenure
55yo
Average Age

Experienced Management: VOR's management team is not considered experienced ( 0.5 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Jean-Paul Kress
Chairman & CEOless than a yearno datano data
Siddhartha Mukherjee
Scientific Founder & Chairman of Scientific Advisory Boardno datano datano data
Malcolm Brenner
Scientific Advisor2.9yrsno datano data
Eric Sievers
Scientific & Clinical Advisorno datano datano data
Daniella Beckman
Independent Director5.5yrsUS$94.80kno data
Olivier Danos
Scientific & Clinical Advisor4.3yrsno datano data
Steven Devine
Scientific & Clinical Advisorno datano datano data
Robert Soiffer
Scientific & Clinical Advisorno datano datano data
Alexander Cumbo
Directorless than a yearno data0%
$ 0
Hans-Peter Kiem
Scientific & Clinical Advisorno datano datano data
Soheil Meshinchi
Scientific & Clinical Advisor5yrsno datano data
Pietro Genovese
Scientific Advisor3yrsno datano data
3.0yrs
Average Tenure
61yo
Average Age

Experienced Board: VOR's board of directors are considered experienced (3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/06 09:56
End of Day Share Price 2026/01/06 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Vor Biopharma Inc. is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Carter GouldBarclays
Justin WalshB. Riley Securities, Inc.